Meitheal Pharmaceuticals, a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, announced it has acquired North America rights to Contepo (fosfomycin for injection) from Nabriva Therapeutics. Contepo is a novel, intravenous (IV), broad spectrum antibiotic with demonstrated activity against most multi-drug resistant (MDR) strains that cause complicated urinary tract infections (cUTI).
Meitheal Pharmaceuticals Expands Specialty Biopharmaceuticals Portfolio with Acquisition of CONTEPO™ (Fosfomycin for Injection) from Nabriva Therapeutics
Meitheal Pharmaceuticals Strengthens Biologics Portfolio with an Exclusive Commercial Licensing Agreement for YUSIMRY®, a Biosimilar of Humira®
Meitheal Pharmaceuticals Announces Recent Business Progress Reinforcing Commitment to Sustainable Generics Development
Meitheal Pharmaceuticals Announces Expansion of Portfolio of Generic Injectable Products
Meitheal Announces Exclusive Commercial Licensing Agreement for Insulin Biosimilars in the U.S.
Meitheal Announces Closing of Senior Secured Credit Facility Agreement for Up to $80 Million with J.P. Morgan
Xentria’s bid to find a new use for TNF inhibitors has landed it with $45 million in the bank. Building on evidence that Remicade improves outcomes in a lung disease, Xentria has persuaded Meitheal Pharmaceuticals to hand over the upfront payment and offer more than $600 million in potential future paydays for North American rights to its candidate.
CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals (“Meitheal”), a fully integrated generic injectables company based in Chicago, Illinois today announced it has joined The Association for Accessible Medicines (AAM), the trade association representing the generics and biosimilars industry. AAM works to ensure more accessibility to generic and biosimilar medicines, and to advance policies that promote sustainability of the accessible medicines industry.
Enforcement Report - Week of September 22, 2021